Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 4Phase 1 3Phase 2/3 1

Status

Completed 3Unknown 1

Sponsor Class

INDUSTRY 2OTHER 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 2Thoracic 1Genitourinary 1

Conditions

Breast Neoplasms 2Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × AZD4547 × Clear all
NCT01824901 2023-06-29

Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer

Eastern Cooperative Oncology Group

Phase 1/2 Completed
2 enrolled 4 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01791985 2022-08-22

RADICAL

Imperial College London

Phase 1/2 Completed
52 enrolled 17 charts
Breast

Breast Neoplasms

NCT05086666 2021-10-21

A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547

Abbisko Therapeutics Co, Ltd

Phase 1/2 Unknown
108 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT01202591 2016-02-11

GLOW

AstraZeneca

Phase 1/2 Completed
127 enrolled 8 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡